EyePoint, Inc. Common Stock vs. 10x Genomics, Inc. Class A Common Stock
EYPT
EyePoint, Inc. Common Stock
$4.87 -66.98%
VS TXG10x Genomics, Inc. Class A Common Stock
$57.99 +3.39%
10x Genomics, Inc. Class A Common Stock (TXG) comes out ahead, leading on 7 of 8 compared factors.
Size & Scale
| EYPT | TXG | |
|---|---|---|
| Market Cap | $1.27 billion | $7.31 billion |
| Revenue (TTM) | $2.79 million | $616.91 million |
| Net Income (TTM) | $-306,643,000 | $-75,125,000 |
TXG leads on 3 of 3 size & scale factors.
Valuation
| EYPT | TXG | |
|---|---|---|
| Price / Book | 7.64 | 8.85 |
| Price / Sales | 455.94 | 11.85 |
EYPT and TXG split the valuation factors evenly.
Profitability
| EYPT | TXG | |
|---|---|---|
| Net Margin | -10994.73% | -12.18% |
| Return on Equity | -184.27% | -9.10% |
TXG leads on 2 of 2 profitability factors.
Risk & Sentiment
| EYPT | TXG | |
|---|---|---|
| Short Interest | 1.22% | 0.42% |
TXG leads on 1 of 1 risk & sentiment factors.
Dig deeper: EYPT overview, EYPT financials, TXG overview, TXG financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.